Tools
Physiology, Placenta
Introduction
The placenta is the medium through which material passes from the maternal circulation to the fetal circulation by passive diffusion or active transport.[1]
Development
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Development
After fertilization of the sperm and ovum, four cell division leads to a morula (16 cells). Around the fourth day after fertilization, the morula enters the uterus as a blastocyst. The blastocyst divides into trophoblast and embryoblast. About 6 to 7 days later, the differentiating blastocyst implants into the uterine decidua. Then, the trophoblast further divides into the syncytiotrophoblast and cytotrophoblast; together, these compose the fetal component of the placenta. These two cell types lay on either side of villi. The cytotrophoblast resides on the inner layer of the chorionic villi. Syncytiotrophoblasts are multinucleated cells that are located on the outer layer of the chorionic villi. In between the syncytiotrophoblast layer, lacunae form to serve as a direct connection to the maternal blood. The remaining cells surrounding the lacunae, called trabeculae, penetrate deep into the uterine wall and, later, develop into the villous trees of the placenta. The maternal blood supply lies in the decidua basalis of the endometrium, which constitutes the maternal component of the placenta.
As the pregnancy progresses, the villous cytotrophoblast slowly disappears from the chorionic villi. Additionally, the villi structure develops to reduce the distance between the maternal blood and fetal vessels — this change benefits maternal-fetal-exchanges. By the end of a pregnancy, five types of villi comprise the placenta: mesenchymal villi, immature intermediate villi, stem villi, mature intermediate villi, and terminal villi. From the mesenchymal villi and immature intermediate villi, about three to five mature intermediate villi grow from the stem villous, and ten to twelve branches of the terminal villi grow from the mature intermediate villi. These villi help communication between the chorionic plate and decidua. Most of the villi float freely in the intervillous space while other villi attach to the decidua as structural stability for the placenta.
- Mesenchymal villi play a significant role early in the first trimester as the most primitive type of villi. The villi are mostly filled with mesenchymal cells and with poorly developed villi. Mesenchymal cells will later differentiate into a variety of other cells including the following: endothelial cells, blood cells, macrophages, myofibroblasts, smooth muscle cells, and fibroblasts.
- Immature intermediate villi are prevalent in the mid-first trimester. These reticular structures contain fluid as well as macrophages called Hofbauer cells. Between the stroma, small arterioles and venules start to develop.
- Stem villi appear condensed with collagen fibers during the mid-first trimester. Additionally, there are few fibroblasts and macrophages as well as muscularized arteries and veins in the villi.
- Mature intermediate villi, in mid-gestation, are bundles of connective tissue with numerous peripheral capillaries as well as some small terminal arterioles and collecting venules.
- Terminal villi mainly function during the late second trimester through the early third trimester. These villi have no stroma and predominantly contain sinusoidal capillaries.[2][3][4][5]
Function
The placenta plays a vital role in maternal-fetal physiology. The placenta has numerous responsibilities:
- Implantation: The syncytiotrophoblast, which later grows as part of the placenta, facilitates implantation by directly invading the wall of the endometrium in the uterus.[1]
- Maternal recognition of pregnancy: Human chorionic gonadotropin (hCG) is synthesized and released from the syncytiotrophoblast to stimulate luteal progesterone production to maintain the pregnancy. Without hCG production, the absence of progesterone would trigger menses and, therefore, the sloughing of the endometrium with the implanted zygote.[6]
- Nutrient and gas exchange: Terminal villi are the functional unit at which maternal-fetal exchange of nutrients and gases occur. Mother's blood provides oxygen, water with electrolytes, hormones, and other nutrients. In exchange, the fetus excretes carbon dioxide, water, urea, hormones, and other waste products. The maternal and fetal circulation do not mix. Instead, blood flow moderates the passive or active transport of nutrients and gases between vasculature.[7][8]
- Fetal protection from any immunologic attack: The placenta holds the ability to metabolize numerous substances and protect against microbial infection. Macrophage in the stroma of the chorionic villi and syncytiotrophoblast play a critical role in the protection of the fetus. Additionally, many leukocytes reside in the decidua of the endometrium to support a successful pregnancy.[9][10]
- Prepare environment: Many hormones are released from the placenta to uphold a pregnancy. The placental growth factor is released from the placenta to prepare the mother’s body for pregnancy in terms of cardiovascular adaption. Additionally, the placental growth factor promotes fetal development and maturity. Human chorionic somatomammotropin (HCS), also known as human placental lactogen (HPL) promotes breast development and alters the metabolism of the mother. It decreases maternal insulin sensitivity so that more glucose is available for the fetus.[1][11]
Abnormalities in the placenta’s function can lead to poor pregnancy outcomes.
Related Testing
The chorionic villus sampling test (CVS) is a diagnostic, ambulatory procedure testing for chromosomal abnormalities. This test is recommended at the time of conception for women above the age of 35 if a parent is a carrier of a genetic disorder, women with abnormal ultrasound results, or women with previous children with chromosome abnormalities. Performance of the test may be transcervically or transabdominally; during the test, a small cell sample is taken from the fetal part of the placenta chorion between the 10th and 13 weeks of pregnancy. The fetus’ chromosomes are karyotyped to diagnose chromosomal abnormalities. There is a risk of miscarriage and, in some literature, limb defects when performing placenta chorion testing before the suggested testing period (before the tenth week). Other complications include vaginal bleeding, infection, rupture of membranes, and fetomaternal hemorrhage. In some cases, results can be inconclusive so that other tests may be necessary. Amniocentesis is an alternative to CVS as both are used to analyze genetic information.[12][13][14]
The combined test is a screening tool used to primarily detect Down syndrome in the first trimester with a low false positive rate. This test is also known to detect trisomy 18 and 13 as well as monosomy X and triploidies at lower accuracy rates. It is comprised of ultrasound to determine nuchal translucency, pregnancy-associated plasma protein-A (PAPP-A) which correlates with aneuploidy, and free beta or total human chorionic gonadotropin (hCG). Ultrasound imaging is performed between 11 and 13 weeks while the collection of serum sample ranges from 9 to 13 weeks. If screening with the combined test suggests chromosomal abnormalities, CVS or amniocentesis should be offered for definitive prenatal diagnosis.[15][16][17]
- Ultrasound is a safe, effective, and easily used imaging study as it functions with no radiation can be used as a diagnostic tool and can be applied bedside. This tool can detect fetal death, diagnose dysmorphologies, and localization of the placenta.[18][19]
- HCG is a hormone synthesized by the syncytiotrophoblast cells in the fetal component of the placenta. The production of hCG in the first trimester is necessary to maintain pregnancy by promoting progesterone secretion by the corpus luteum. hCG levels peak between weeks 8 and 10. After the tenth week, hCG levels plateau and the placenta takes responsibility to produce progesterone. Blood hCG can be detected during the first week after fertilization while at-home urine pregnancy tests can detect hCG two weeks after fertilization. It has several functions including the following: promotion of progesterone production by the corpus luteal cells, angiogenesis in the uterus, growth of uterus and fetus, cell differentiation to increase syncytiotrophoblast cells, suppress immunologic attack by mother on fetus, suppress myometrial contractions during pregnancy, development of umbilical cord, and affects maternal brainstem causing morning sickness.[20][21][22][23]
- PAPP-A is a hormone produced by the fetus and the placenta in pregnancy. This hormone promotes placental growth and function through the facilitation of the insulin-like growth factor (IGF). Therefore, PAPP-A levels increase with time of pregnancy. In some studies, the thickness of placenta also correlates with higher blood levels of PAPP-A. Chromosomal abnormalities, like trisomy 21, are significantly correlated with low blood PAPP-A.[24][25]
Placental growth factor (PIGF) is a potent angiogenic protein factor produced by the syncytiotrophoblast. The purpose of PIGF is to facilitate the development and maturation of the placental vasculature. Low PIGF suggests placental dysfunction associated with pre-eclampsia and intrauterine growth restriction.[26][27]
Human chorionic somatomammotropin (HCS), also known as human placental lactogen (HPL) is produced by the syncytiotrophoblast starting in week 6. HCS functions to promote breast development and decrease maternal insulin sensitivity and increases glucose availability for the fetus. Literature indicates the measurement of HCS is clinically relevant during the third trimester as blood HCS results can predict the outcome by indicating functionality of the placenta and, indirectly, fetal growth.[28][29]
Pathophysiology
Intrauterine growth restriction (IUGR) is a condition in which fetal growth is less than the tenth percentile of the predicted weight for gestational age. IUGR can lead to fetal morbidity and mortality. The restriction of growth can be the result of maternal, fetal, and placental causes. Most fetuses develop IUGR secondary to maternal causes like preeclampsia, poor nutrition, drug addiction, alcohol use, and tobacco use. Retardation occurs symmetrically in all organs with fetal causes like chromosomal abnormalities, congenital malformations, and congenital infections. Additionally, abruptio placentae, placental infarction, and a single umbilical artery (instead of two) cause asymmetric growth retardation, which is also known as “head sparing.” The common factor among these risk factors is that blood flow to the fetus is compromised either through vasoconstriction or loss of blood. Diagnoses of IUGR is difficult in utero. Therefore, the detection of highly associated conditions like unexplained oligohydramnios (about 85% of IUGR infants also have oligohydramnios) should warrant further evaluation. Assessment for IUGR includes doppler sonography as well as analysis of estimated fetal weight, the volume of amniotic fluid, and mother’s blood pressure status.[30][31][32][33][34]
Choriocarcinoma is a germ cell malignant tumor of the cytotrophoblast and syncytiotrophoblast cells. The tumor cells mimic placental tissue; however, there are no villi to exchange nutrients. Choriocarcinoma can develop into a small hemorrhagic tumor and can easily invade maternal blood vessels leading to early hematogenous spread throughout the circulation. Patients usually present with a uterus larger than expected for gestational age. The evaluation includes ultrasound which shows a “snowstorm appearance.” Blood tests typically show elevated beta hCG, which is produced by syncytiotrophoblast. High levels of hCG can lead to thecal cysts in the ovary. Treatment is dilation and curettage with follow-up monitoring with beta-hCG levels. This germ cell tumor usually responds poorly to chemotherapy; however, there are some cases in which chemotherapy after resection may result in a successful outcome.[35][36][37][38]
Preeclampsia, usually arising in the third trimester, is pregnancy-induced hypertension by increased total peripheral resistance but the pathogenesis is poorly understood. Literature provides evidence for an imbalance of angiogenic and anti-antigenic factors as well as defective spiral artery remodeling, which eventually leads to the former hypothesis. This disproportion favors anti-angiogenic factors leading to endothelial dysfunction in the maternal organs. In terms of diagnosing pre-eclampsia, hypertension couples with one of the following: elevated liver enzymes, reduced liver or kidney function, or pulmonary or cerebral edema. Preeclampsia resolves with delivery and removal of the maternal-fetal vascular interface. Methyldopa and magnesium sulfate are the recommendations for control of hypertension.[39][40][41]
Clinical Significance
Placenta previa is the implantation of the placenta over the cervical os, which usually presents as painless vaginal bleeding in the third trimester. Additionally, the uterus is soft and non-tender on physical exam. The fetus is usually not in distress. Risk factors include a history of cesarean section or multiple vaginal births. A transabdominal ultrasound localizes the placenta, but placenta previa diagnosis is by transvaginal ultrasound. In these cases, mother and fetus must undergo careful monitoring and delivery is often by cesarean section.[44][45][46]
Placental abruption (abruptio placentae), complete or partial, is the premature separation of the placenta from the decidua basalis, which is the number one cause of vaginal bleeding late in pregnancy. Unlike placenta previa, uterine bleeding is painful with uterine contractions and fetal distress is usually present. Commonly, bleeding is due to rupture of maternal vessels, but fetal-placental vessels can also cause the separation. Ultrasound is the preferred diagnostic tool. Conditions affecting circulation act as risk factors and include hypertension, tobacco, cocaine, trauma, and premature rupture of membranes. Treatment includes the delivery of the baby. However, placental abruption frequently results in stillbirth.[47][48][49]
Placenta accreta spectrum (PAS), formally known as morbidly adherent placenta, describes the improper attachment and separation of the placenta to a defective decidual layer of the endometrium. Women with maternal age, multiparity, or history of C-section or uterine surgery are at high risk for abnormal placenta adherence. Discovery of this condition is on ultrasound before delivery; however, there is difficulty with placental separation after birth which causes postpartum bleeding. Therefore, prenatal diagnosis is important to prepare for difficult labor, which may involve surgery. If findings are unclear with ultrasound, magnetic resonance imaging (MRI) can clarify the diagnosis. There are three types of morbidly adherent placenta ranging from various depths of infiltration.[50][51][52]
- Placenta accrete, the most common type is the implantation of placenta onto the myometrium rather than the decidua.[52]
- Placenta increta describes the placenta intervening the myometrium but avoiding invasion outside the uterus.[52]
- Placenta percreta is the deepest penetrating of the three types as the placenta pushes through the myometrium and into the uterine wall. In some cases, the placental cells can reach out of the uterus and invade the rectum or bladder.[52]
References
Cross JC. Placental function in development and disease. Reproduction, fertility, and development. 2006:18(1-2):71-6 [PubMed PMID: 16478604]
Level 3 (low-level) evidenceSoares MJ, Iqbal K, Kozai K. Hypoxia and Placental Development. Birth defects research. 2017 Oct 16:109(17):1309-1329. doi: 10.1002/bdr2.1135. Epub [PubMed PMID: 29105383]
McConkey CA, Delorme-Axford E, Nickerson CA, Kim KS, Sadovsky Y, Boyle JP, Coyne CB. A three-dimensional culture system recapitulates placental syncytiotrophoblast development and microbial resistance. Science advances. 2016 Mar:2(3):e1501462. doi: 10.1126/sciadv.1501462. Epub 2016 Mar 4 [PubMed PMID: 26973875]
Level 3 (low-level) evidenceHuppertz B. The anatomy of the normal placenta. Journal of clinical pathology. 2008 Dec:61(12):1296-302. doi: 10.1136/jcp.2008.055277. Epub 2008 Aug 28 [PubMed PMID: 18755720]
Kuhlmann RS, Werner AL, Abramowicz J, Warsof SL, Arrington J, Levy DL. Placental histology in fetuses between 18 and 23 weeks' gestation with abnormal karyotype. American journal of obstetrics and gynecology. 1990 Oct:163(4 Pt 1):1264-70 [PubMed PMID: 2220940]
Theofanakis C, Drakakis P, Besharat A, Loutradis D. Human Chorionic Gonadotropin: The Pregnancy Hormone and More. International journal of molecular sciences. 2017 May 14:18(5):. doi: 10.3390/ijms18051059. Epub 2017 May 14 [PubMed PMID: 28505106]
Sengupta A, Biswas P, Jayaraman G, Guha SK. Understanding utero-placental blood flow in normal and hypertensive pregnancy through a mathematical model. Medical & biological engineering & computing. 1997 May:35(3):223-30 [PubMed PMID: 9246856]
Level 3 (low-level) evidenceSchmiedl UP, Komarniski K, Winter TC, Luna JA, Cyr DR, Ruppenthal G, Schlief R. Assessment of fetal and placental blood flow in primates using contrast enhanced ultrasonography. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 1998 Feb:17(2):75-80; discussion 81-2 [PubMed PMID: 9527576]
Level 3 (low-level) evidenceGude NM, Roberts CT, Kalionis B, King RG. Growth and function of the normal human placenta. Thrombosis research. 2004:114(5-6):397-407 [PubMed PMID: 15507270]
Robbins JR, Bakardjiev AI. Pathogens and the placental fortress. Current opinion in microbiology. 2012 Feb:15(1):36-43. doi: 10.1016/j.mib.2011.11.006. Epub 2011 Dec 12 [PubMed PMID: 22169833]
Level 3 (low-level) evidenceAasa KL, Zavan B, Luna RL, Wong PG, Ventura NM, Tse MY, Carmeliet P, Adams MA, Pang SC, Croy BA. Placental growth factor influences maternal cardiovascular adaptation to pregnancy in mice. Biology of reproduction. 2015 Feb:92(2):44. doi: 10.1095/biolreprod.114.124677. Epub 2014 Dec 23 [PubMed PMID: 25537372]
Level 3 (low-level) evidenceWapner RJ. Chorionic villus sampling. Obstetrics and gynecology clinics of North America. 1997 Mar:24(1):83-110 [PubMed PMID: 9086520]
Evans MI, Koppich FC 3rd, Nemitz B, Quigg MH, Zador IE. Early genetic amniocentesis and chorionic villus sampling. Expanding the opportunities for early prenatal diagnosis. The Journal of reproductive medicine. 1988 May:33(5):450-2 [PubMed PMID: 3385699]
Shulman LP, Elias S. Amniocentesis and chorionic villus sampling. The Western journal of medicine. 1993 Sep:159(3):260-8 [PubMed PMID: 8236967]
Lee FK, Chen LC, Cheong ML, Chou CY, Tsai MS. First trimester combined test for Down syndrome screening in unselected pregnancies - a report of a 13-year experience. Taiwanese journal of obstetrics & gynecology. 2013 Dec:52(4):523-6. doi: 10.1016/j.tjog.2013.10.012. Epub [PubMed PMID: 24411037]
Schuchter K, Hafner E, Stangl G, Metzenbauer M, Höfinger D, Philipp K. The first trimester 'combined test' for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenatal diagnosis. 2002 Mar:22(3):211-5 [PubMed PMID: 11920896]
Santorum M, Wright D, Syngelaki A, Karagioti N, Nicolaides KH. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2017 Jun:49(6):714-720. doi: 10.1002/uog.17283. Epub 2017 Apr 26 [PubMed PMID: 27549925]
Akhter MS. The use of ultrasound in obstetrics and gynecology. JPMA. The Journal of the Pakistan Medical Association. 1976 Mar:26(3):64-7 [PubMed PMID: 819676]
Novak CM, Graham EM. Obstetric management, tests, and technologies that impact childhood development. Developmental medicine and child neurology. 2019 Sep:61(9):1002-1007. doi: 10.1111/dmcn.14160. Epub 2019 Jan 28 [PubMed PMID: 30688360]
Cole LA. Biological functions of hCG and hCG-related molecules. Reproductive biology and endocrinology : RB&E. 2010 Aug 24:8():102. doi: 10.1186/1477-7827-8-102. Epub 2010 Aug 24 [PubMed PMID: 20735820]
Merz WE. The primate placenta and human chorionic gonadotropin. Experimental and clinical endocrinology. 1994:102(3):222-34 [PubMed PMID: 7995344]
Level 3 (low-level) evidenceCole LA. hCG physiology. Placenta. 2013 Dec:34(12):1257. doi: 10.1016/j.placenta.2013.02.011. Epub 2013 Oct 7 [PubMed PMID: 24157352]
Level 3 (low-level) evidenceKumar P, Magon N. Hormones in pregnancy. Nigerian medical journal : journal of the Nigeria Medical Association. 2012 Oct:53(4):179-83. doi: 10.4103/0300-1652.107549. Epub [PubMed PMID: 23661874]
Mesdaghi-Nia E, Behrashi M, Saeidi A, Abedzadeh Kalahroodi M, Sehat M. Association between PAPP-A and placental thickness. International journal of reproductive biomedicine. 2016 Jun:14(6):421-6 [PubMed PMID: 27525326]
Leguy MC, Brun S, Pidoux G, Salhi H, Choiset A, Menet MC, Gil S, Tsatsaris V, Guibourdenche J. Pattern of secretion of pregnancy-associated plasma protein-A (PAPP-A) during pregnancies complicated by fetal aneuploidy, in vivo and in vitro. Reproductive biology and endocrinology : RB&E. 2014 Dec 28:12():129. doi: 10.1186/1477-7827-12-129. Epub 2014 Dec 28 [PubMed PMID: 25543334]
Level 2 (mid-level) evidenceAthanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta. 1998 Sep:19(7):465-73 [PubMed PMID: 9778119]
Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. Journal of human hypertension. 2017 Dec:31(12):782-786. doi: 10.1038/jhh.2017.61. Epub 2017 Aug 24 [PubMed PMID: 29115294]
Ayala AR, Avila MA, Sereno O, Sánchez V, López Garcia R. [Human chorionic somatomammotropin (HCS) and placental volume]. Ginecologia y obstetricia de Mexico. 1989 Dec:57():321-4 [PubMed PMID: 2486972]
Belleville F, Lasbennes A, Nabet P, Paysant P. HCS regulation in cultured placenta: action of glucose. Acta endocrinologica. 1979 Oct:92(2):336-46 [PubMed PMID: 494996]
Sharma D, Shastri S, Farahbakhsh N, Sharma P. Intrauterine growth restriction - part 1. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2016 Dec:29(24):3977-87. doi: 10.3109/14767058.2016.1152249. Epub 2016 Mar 7 [PubMed PMID: 26856409]
Baschat AA, Hecher K. Fetal growth restriction due to placental disease. Seminars in perinatology. 2004 Feb:28(1):67-80 [PubMed PMID: 15058904]
Sharma D, Farahbakhsh N, Shastri S, Sharma P. Intrauterine growth restriction - part 2. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2016 Dec:29(24):4037-48. doi: 10.3109/14767058.2016.1154525. Epub 2016 Mar 15 [PubMed PMID: 26979578]
Lin CC, Sheikh Z, Lopata R. The association between oligohydramnios and intrauterine growth retardation. Obstetrics and gynecology. 1990 Dec:76(6):1100-4 [PubMed PMID: 2234721]
Philipson EH, Sokol RJ, Williams T. Oligohydramnios: clinical associations and predictive value for intrauterine growth retardation. American journal of obstetrics and gynecology. 1983 Jun 1:146(3):271-8 [PubMed PMID: 6859136]
Smith HO, Kohorn E, Cole LA. Choriocarcinoma and gestational trophoblastic disease. Obstetrics and gynecology clinics of North America. 2005 Dec:32(4):661-84 [PubMed PMID: 16310678]
Wreczycka-Cegielny P, Cegielny T, Oplawski M, Sawicki W, Kojs Z. Current treatment options for advanced choriocarcinoma on the basis of own case and review of the literature. Ginekologia polska. 2018:89(12):711-715. doi: 10.5603/GP.a2018.0120. Epub [PubMed PMID: 30618041]
Level 3 (low-level) evidence. Choriocarcinoma and gestational trophoblastic disease. The Western journal of medicine. 1976 Mar:124(3):219-25 [PubMed PMID: 176828]
Liu S, Fan C, Feng F, Xiang Y, Wan X, Ren T. Prognosis of gestational choriocarcinoma diagnosed incidentally during laparoscopy for a presumed cornual pregnancy: a report of five cases. Cancer biology & medicine. 2017 May:14(2):191-193. doi: 10.20892/j.issn.2095-3941.2017.0004. Epub [PubMed PMID: 28607811]
Level 3 (low-level) evidenceGathiram P, Moodley J. Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovascular journal of Africa. 2016 Mar-Apr:27(2):71-8. doi: 10.5830/CVJA-2016-009. Epub [PubMed PMID: 27213853]
Jim B, Karumanchi SA. Preeclampsia: Pathogenesis, Prevention, and Long-Term Complications. Seminars in nephrology. 2017 Jul:37(4):386-397. doi: 10.1016/j.semnephrol.2017.05.011. Epub [PubMed PMID: 28711078]
Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. Clinical journal of the American Society of Nephrology : CJASN. 2016 Jun 6:11(6):1102-13. doi: 10.2215/CJN.12081115. Epub 2016 Apr 19 [PubMed PMID: 27094609]
Kınay T, Küçük C, Kayıkçıoğlu F, Karakaya J. Severe Preeclampsia versus HELLP Syndrome: Maternal and Perinatal Outcomes at {34 and ≥34 Weeks' Gestation. Balkan medical journal. 2015 Oct:32(4):359-63. doi: 10.5152/balkanmedj.2015.15777. Epub 2015 Oct 1 [PubMed PMID: 26740894]
Gupte S, Wagh G. Preeclampsia-eclampsia. Journal of obstetrics and gynaecology of India. 2014 Feb:64(1):4-13. doi: 10.1007/s13224-014-0502-y. Epub 2014 Jan 31 [PubMed PMID: 24587599]
Alouini S, Megier P, Fauconnier A, Huchon C, Fievet A, Ramos A, Megier C, Valéry A. Diagnosis and management of placenta previa and low placental implantation. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2020 Oct:33(19):3221-3226. doi: 10.1080/14767058.2019.1570118. Epub 2019 Jan 27 [PubMed PMID: 30688129]
Ratiu AC, Crisan DC. A prospective evaluation and management of different types of placenta praevia using parallel vertical compression suture to preserve uterus. Medicine. 2018 Nov:97(46):e13253. doi: 10.1097/MD.0000000000013253. Epub [PubMed PMID: 30431609]
Mabie WC. Placenta previa. Clinics in perinatology. 1992 Jun:19(2):425-35 [PubMed PMID: 1617885]
Schmidt P, Skelly CL, Raines DA. Placental Abruption. StatPearls. 2023 Jan:(): [PubMed PMID: 29493960]
Oyelese Y, Ananth CV. Placental abruption. Obstetrics and gynecology. 2006 Oct:108(4):1005-16 [PubMed PMID: 17012465]
Tikkanen M. Placental abruption: epidemiology, risk factors and consequences. Acta obstetricia et gynecologica Scandinavica. 2011 Feb:90(2):140-9. doi: 10.1111/j.1600-0412.2010.01030.x. Epub 2010 Dec 7 [PubMed PMID: 21241259]
Society of Gynecologic Oncology, American College of Obstetricians and Gynecologists and the Society for Maternal–Fetal Medicine, Cahill AG, Beigi R, Heine RP, Silver RM, Wax JR. Placenta Accreta Spectrum. American journal of obstetrics and gynecology. 2018 Dec:219(6):B2-B16. doi: 10.1016/j.ajog.2018.09.042. Epub [PubMed PMID: 30471891]
Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. American journal of obstetrics and gynecology. 2018 Jan:218(1):75-87. doi: 10.1016/j.ajog.2017.05.067. Epub 2017 Jun 24 [PubMed PMID: 28599899]
Silver RM, Branch DW. Placenta Accreta Spectrum. The New England journal of medicine. 2018 Apr 19:378(16):1529-1536. doi: 10.1056/NEJMcp1709324. Epub [PubMed PMID: 29669225]